News and Updates

Breakthrough T1D had the pleasure of speaking with Patti Columbe, a participant in Vertex’s pivotal trial for the manufactured islet therapy zimislecel (formerly VX-880). Patti has been living with type 1 diabetes (T1D) for nearly 39 years. This is one of the most exciting T1D trials in terms of getting us closer to cures for […]

Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.

Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.

Breakthrough T1D, Breakthrough T1D Canada, and the Stem Cell Network (SCN) have partnered to support cell therapy research in Canada.

The Medical Affairs team is working to ensure the clinical adoption of forthcoming manufactured cell therapies.

This meeting focused on the role of the EU in addressing the needs of the T1D community and accelerating T1D breakthroughs.

Breakthrough T1D's Advocacy efforts contribute to clear and efficient policies and secure government funding for manufactured cell therapies.

Breakthrough T1D's Medical Affairs team hosted experts in islet transplantation to discuss a clinical roadmap for manufactured cell therapies.

Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how we’re going to make them a reality.

Breakthrough T1D is funding research that supports manufactured islet cell source, survival, and protection and is also driving initiatives to unlock access to manufactured islet therapies for people with T1D.